8BWW

Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs

  • Classification: DE NOVO PROTEIN
  • Organism(s): Homo sapiens
  • Mutation(s): Yes 

  • Deposited: 2022-12-07 Released: 2023-09-06 
  • Deposition Author(s): Diehl, C.
  • Funding Organization(s): Swedish Research Council

Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 60 
  • Conformers Submitted: 10 
  • Selection Criteria: structures with the least restraint violations 

wwPDB Validation   3D Report Full Report


This is version 2.1 of the entry. See complete history


Literature

Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs.

Petruk, G.Puthia, M.Samsudin, F.Petrlova, J.Olm, F.Mittendorfer, M.Hyllen, S.Edstrom, D.Stromdahl, A.C.Diehl, C.Ekstrom, S.Walse, B.Kjellstrom, S.Bond, P.J.Lindstedt, S.Schmidtchen, A.

(2023) Nat Commun 14: 6097-6097

  • DOI: https://doi.org/10.1038/s41467-023-41702-y
  • Primary Citation of Related Structures:  
    8BWW

  • PubMed Abstract: 

    There is a clinical need for conceptually new treatments that target the excessive activation of inflammatory pathways during systemic infection. Thrombin-derived C-terminal peptides (TCPs) are endogenous anti-infective immunomodulators interfering with CD14-mediated TLR-dependent immune responses. Here we describe the development of a peptide-based compound for systemic use, sHVF18, expressing the evolutionarily conserved innate structural fold of natural TCPs. Using a combination of structure- and in silico-based design, nuclear magnetic resonance spectroscopy, biophysics, mass spectrometry, cellular, and in vivo studies, we here elucidate the structure, CD14 interactions, protease stability, transcriptome profiling, and therapeutic efficacy of sHVF18. The designed peptide displays a conformationally stabilized, protease resistant active innate fold and targets the LPS-binding groove of CD14. In vivo, it shows therapeutic efficacy in experimental models of endotoxin shock in mice and pigs and increases survival in mouse models of systemic polymicrobial infection. The results provide a drug class based on Nature´s own anti-infective principles.


  • Organizational Affiliation

    Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, SE-22184, Lund, Sweden. ganna.petruk@med.lu.se.


Macromolecules

Find similar proteins by:  Sequence   |   3D Structure  

Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Thrombin light chain18Homo sapiensMutation(s): 2 
EC: 3.4.21.5
UniProt & NIH Common Fund Data Resources
Find proteins for P00734 (Homo sapiens)
Explore P00734 
Go to UniProtKB:  P00734
PHAROS:  P00734
GTEx:  ENSG00000180210 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP00734
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Modified Residues  1 Unique
IDChains TypeFormula2D DiagramParent
MK8
Query on MK8
A
L-PEPTIDE LINKINGC7 H15 N O2LEU
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 60 
  • Conformers Submitted: 10 
  • Selection Criteria: structures with the least restraint violations 

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data

  • Released Date: 2023-09-06 
  • Deposition Author(s): Diehl, C.

Funding OrganizationLocationGrant Number
Swedish Research CouncilSweden2017-02341, 2020-02016, 2021-06388

Revision History  (Full details and data files)

  • Version 1.0: 2023-09-06
    Type: Initial release
  • Version 1.1: 2023-09-27
    Changes: Database references, Structure summary
  • Version 1.2: 2023-10-11
    Changes: Database references
  • Version 2.0: 2023-11-15
    Changes: Atomic model, Data collection
  • Version 2.1: 2024-11-20
    Changes: Database references, Structure summary